<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03979859</url>
  </required_header>
  <id_info>
    <org_study_id>W 4873 02</org_study_id>
    <nct_id>NCT03979859</nct_id>
  </id_info>
  <brief_title>Evaluate The Safety, Tolerability and Pharmacokinetics Of Multiple Ascending Oral Doses Of WCK 4873 In Healthy Adult Volunteers</brief_title>
  <official_title>Double-Blind, Randomized, Placebo-Controlled Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Multiple Ascending Oral Doses Of WCK 4873 In Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wockhardt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wockhardt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, double-blind, single center, placebo-controlled, sequential&#xD;
      cohort study in a maximum of 3 cohorts of 10 healthy male and/or female subjects each.&#xD;
      Subjects in Cohorts 1, 2 and 3 will receive ascending multiple oral doses of WCK 4873 or&#xD;
      matching placebo once daily on Days 1 to 7. Dosing will be conducted under fed conditions on&#xD;
      each dosing day. The dose levels to be administered will be based on the safety, tolerability&#xD;
      and PK results of the single dose and food effect study (W 4873 01 study; PRA-code&#xD;
      WOE384EC-123841).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 20, 2013</start_date>
  <completion_date type="Actual">December 30, 2013</completion_date>
  <primary_completion_date type="Actual">December 5, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessing incidence of treatment emergent AEs</measure>
    <time_frame>Day 24</time_frame>
    <description>By abnormal clinical laboratory (including liver function tests) findings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessing incidence of treatment emergent AEs</measure>
    <time_frame>Day 24</time_frame>
    <description>By variation in physical examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessing incidence of treatment emergent AEs</measure>
    <time_frame>Day 24</time_frame>
    <description>By abnormal findings in eye movement test and visual acuity test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessing incidence of treatment emergent AEs</measure>
    <time_frame>Day 24</time_frame>
    <description>By abnormal vital signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessing incidence of treatment emergent AEs</measure>
    <time_frame>Day 24</time_frame>
    <description>variations in 12-lead electrocardiogram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure the pharmacokinetic parameter: Area Under Curve (AUC)</measure>
    <time_frame>Day 10</time_frame>
    <description>plasma PK parameters area under curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure the pharmacokinetic parameter-plasma PK concentration</measure>
    <time_frame>Day 10</time_frame>
    <description>Plasma concentration -Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure the pharmacokinetic parameter- Time</measure>
    <time_frame>Day 10</time_frame>
    <description>Plasma PK parameter- Tmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure the pharmacokinetic parameter- Time</measure>
    <time_frame>Day 10</time_frame>
    <description>Plasma PK parameter- T1/2</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>WCK 4873</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 and 400 mg tablets Dosage form : Oral tablets Doses : To be determined based on the safety, tolerability and PK results of the single dose and food effect study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Visually matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WCK 4873</intervention_name>
    <arm_group_label>WCK 4873</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI : 18.0-30.0 kg/m2 (Body Mass Index [BMI] [kg/m2] = Body weight [kg] Height2 [m2])&#xD;
&#xD;
          -  Ability and willingness to abstain from alcohol, methylxanthine-containing beverages&#xD;
             or food (coffee, tea, cola, chocolate, &quot;power-drinks&quot;), grapefruit (juice) from 48 h&#xD;
             prior to entry in the clinical research center until discharge&#xD;
&#xD;
          -  Medical history without major pathology as judged by the Principal Investigator&#xD;
&#xD;
          -  Resting supine blood pressure 90-139 (systolic) / 40-89 (diastolic) mmHg, a resting&#xD;
             pulse rate of 40 beats per minute or higher, and showing no clinically relevant&#xD;
             deviations as judged by the Principal Investigator&#xD;
&#xD;
          -  Computerized 12-lead electrocardiogram (ECG) recording without signs of clinically&#xD;
             relevant pathology or showing no clinically relevant deviations as judged by the&#xD;
             Principal -Investigator. QTcF should be &lt;450 ms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous participation in the current study&#xD;
&#xD;
          -  Evidence of clinically relevant pathology&#xD;
&#xD;
          -  Mental handicap&#xD;
&#xD;
          -  History of Myasthenia Gravis&#xD;
&#xD;
          -  History of hepatitis and/or jaundice associated with the use of any antibiotic&#xD;
&#xD;
          -  Congenital prolongation of the QTc interval, ongoing proarrhythmic conditions such as&#xD;
             uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia&#xD;
&#xD;
          -  History of relevant drug and/or food allergies&#xD;
&#xD;
          -  Regular/routine treatment with non-topical medications within 30 days prior to entry&#xD;
             into the clinical research center&#xD;
&#xD;
          -  Smoking within 60 days prior to drug administration and through the follow-up visit&#xD;
&#xD;
          -  History of alcohol abuse or drug addiction (including soft drugs like cannabis&#xD;
             products)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <last_update_submitted>June 6, 2019</last_update_submitted>
  <last_update_submitted_qc>June 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nafithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

